Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant

We studied the natural inhibitors (NI) of blood coagulation and fibrinolysis in 50 patients with lupus anticoagulant (LA), in order to identify possible alterations of these NI, that could favour thrombotic manifestations. We found no statistically significant difference in antithrombin III, protein...

Descripción completa

Guardado en:

Detalles Bibliográficos
Publicado:	1992
Materias:	antithrombin iii blood clotting inhibitor lupus anticoagulant plasminogen activator inhibitor protein c protein s adolescent adult article child controlled study female human major clinical study male systemic lupus erythematosus thrombosis Abortion, Habitual Adolescent Adult Antiplasmin Antithrombin III Autoimmune Diseases Blood Coagulation Child Comparative Study Female Fibrinolysis Hematologic Diseases Human Infection Lupus Coagulation Inhibitor Lupus Erythematosus, Systemic Male Middle Age Neoplasms Plasminogen Activator Inhibitor 1 Pregnancy Protein C Protein S Thrombosis
Acceso en línea:	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09575235_v3_n6_p765_Kordich http://hdl.handle.net/20.500.12110/paper_09575235_v3_n6_p765_Kordich
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	paper:paper_09575235_v3_n6_p765_Kordich
record_format	dspace
spelling	paper:paper_09575235_v3_n6_p765_Kordich2023-06-08T15:56:38Z Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant antithrombin iii blood clotting inhibitor lupus anticoagulant plasminogen activator inhibitor protein c protein s adolescent adult article child controlled study female human major clinical study male systemic lupus erythematosus thrombosis Abortion, Habitual Adolescent Adult Antiplasmin Antithrombin III Autoimmune Diseases Blood Coagulation Child Comparative Study Female Fibrinolysis Hematologic Diseases Human Infection Lupus Coagulation Inhibitor Lupus Erythematosus, Systemic Male Middle Age Neoplasms Plasminogen Activator Inhibitor 1 Pregnancy Protein C Protein S Thrombosis We studied the natural inhibitors (NI) of blood coagulation and fibrinolysis in 50 patients with lupus anticoagulant (LA), in order to identify possible alterations of these NI, that could favour thrombotic manifestations. We found no statistically significant difference in antithrombin III, protein C and α2-antiplasmin between controls and patients with LA, irrespective of their clinical manifestations. We found an increase of plasminogen activator inhibitor (PAI, P < 0.001) and a decrease of free protein S (PS(f), P < 0.001) and total protein S (PS(t), 0.01 < P < 0.05) in the patients with LA when compared with the control group. We found no difference in the levels of NI between patients with thrombosis (n = 19) and without thrombosis (n = 31) nor between patients with (n = 25) or without thrombosis and/or foetal loss (n = 25). In contrast, we observed a decrease of PS(f) in women with foetal loss (n = 10) as compared with women without foetal loss (n = 22, 0.01 < P < 0.05) and a decrease of PS(f) when comparing 19 patients with systemic lupus erythematosus (SLE) with 31 patients without SLE (0.01 < P < 0.05). These findings show that the patients with LA had several abnormalities in the NI system, but there was no significant association between levels of PAI, PS(f), PS(t) and a history of thrombosis. 1992 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09575235_v3_n6_p765_Kordich http://hdl.handle.net/20.500.12110/paper_09575235_v3_n6_p765_Kordich
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	antithrombin iii blood clotting inhibitor lupus anticoagulant plasminogen activator inhibitor protein c protein s adolescent adult article child controlled study female human major clinical study male systemic lupus erythematosus thrombosis Abortion, Habitual Adolescent Adult Antiplasmin Antithrombin III Autoimmune Diseases Blood Coagulation Child Comparative Study Female Fibrinolysis Hematologic Diseases Human Infection Lupus Coagulation Inhibitor Lupus Erythematosus, Systemic Male Middle Age Neoplasms Plasminogen Activator Inhibitor 1 Pregnancy Protein C Protein S Thrombosis
spellingShingle	antithrombin iii blood clotting inhibitor lupus anticoagulant plasminogen activator inhibitor protein c protein s adolescent adult article child controlled study female human major clinical study male systemic lupus erythematosus thrombosis Abortion, Habitual Adolescent Adult Antiplasmin Antithrombin III Autoimmune Diseases Blood Coagulation Child Comparative Study Female Fibrinolysis Hematologic Diseases Human Infection Lupus Coagulation Inhibitor Lupus Erythematosus, Systemic Male Middle Age Neoplasms Plasminogen Activator Inhibitor 1 Pregnancy Protein C Protein S Thrombosis Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant
topic_facet	antithrombin iii blood clotting inhibitor lupus anticoagulant plasminogen activator inhibitor protein c protein s adolescent adult article child controlled study female human major clinical study male systemic lupus erythematosus thrombosis Abortion, Habitual Adolescent Adult Antiplasmin Antithrombin III Autoimmune Diseases Blood Coagulation Child Comparative Study Female Fibrinolysis Hematologic Diseases Human Infection Lupus Coagulation Inhibitor Lupus Erythematosus, Systemic Male Middle Age Neoplasms Plasminogen Activator Inhibitor 1 Pregnancy Protein C Protein S Thrombosis
description	We studied the natural inhibitors (NI) of blood coagulation and fibrinolysis in 50 patients with lupus anticoagulant (LA), in order to identify possible alterations of these NI, that could favour thrombotic manifestations. We found no statistically significant difference in antithrombin III, protein C and α2-antiplasmin between controls and patients with LA, irrespective of their clinical manifestations. We found an increase of plasminogen activator inhibitor (PAI, P < 0.001) and a decrease of free protein S (PS(f), P < 0.001) and total protein S (PS(t), 0.01 < P < 0.05) in the patients with LA when compared with the control group. We found no difference in the levels of NI between patients with thrombosis (n = 19) and without thrombosis (n = 31) nor between patients with (n = 25) or without thrombosis and/or foetal loss (n = 25). In contrast, we observed a decrease of PS(f) in women with foetal loss (n = 10) as compared with women without foetal loss (n = 22, 0.01 < P < 0.05) and a decrease of PS(f) when comparing 19 patients with systemic lupus erythematosus (SLE) with 31 patients without SLE (0.01 < P < 0.05). These findings show that the patients with LA had several abnormalities in the NI system, but there was no significant association between levels of PAI, PS(f), PS(t) and a history of thrombosis.
title	Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant
title_short	Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant
title_full	Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant
title_fullStr	Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant
title_full_unstemmed	Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant
title_sort	natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant
publishDate	1992
url	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09575235_v3_n6_p765_Kordich http://hdl.handle.net/20.500.12110/paper_09575235_v3_n6_p765_Kordich
_version_	1768546683990310912

Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant

Ejemplares similares